Skip to content

Study · Case report or series · n = 1 · 2008

3 results

Exenatide and acute pancreatitis.

Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A

The Journal of the Association of Physicians of India1 Dec 2008Cited by 32 (Europe PMC)

PMID19322980 (opens in a new tab)PepBankPUB-19322980
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman with T2D, gastrointestinal disturbances began on the first day of exenatide injection.

    In plain wordsA woman with T2D developed digestive problems on her first day of exenatide injections.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableGastrointestinal disturbances
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    She had gastrointestinal disturbances, since the first day of the injection.
    1 context sentence
    Summary · context
    For a female, type 2 diabetic patient, with 4 years duration of diabetes, Exenatide (Byetta) was prescribed as glycaemic control was not satisfactory along with Glimepiride and Metformin.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with T2D receiving exenatide, acute pancreatitis developed from the eighth day and was confirmed by investigations.

    In plain wordsA woman with T2D developed confirmed acute pancreatitis from the eighth day of exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAcute pancreatitis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    From the eighth day she developed signs of acute pancreatitis which was confirmed with CT-Scan and biochemical investigations.
    1 context sentence
    Summary · context
    For a female, type 2 diabetic patient, with 4 years duration of diabetes, Exenatide (Byetta) was prescribed as glycaemic control was not satisfactory along with Glimepiride and Metformin.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with pancreatitis during exenatide exposure, symptoms subsided after withdrawal and pancreatitis treatment.

    In plain wordsThe woman's symptoms subsided after exenatide stopped and she received pancreatitis treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSymptoms after withdrawal and treatment
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided.
    1 context sentence
    Summary · context
    For a female, type 2 diabetic patient, with 4 years duration of diabetes, Exenatide (Byetta) was prescribed as glycaemic control was not satisfactory along with Glimepiride and Metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.